fbpx COVID-19 (Coronavirus): ADB's Response | Asian Development Bank

COVID-19 (Coronavirus): ADB's Response

ADB is supporting its developing members in responding to the COVID-19 pandemic through finance, knowledge, and partnerships.

In the Spotlight

Video | 20 May 2022

Learning Losses: How Students Can Overcome the Cost of COVID-19 (ADB Insight Full Episode)

ADB Economist Rhea Molato-Gayares discusses the short- and long-term impacts students are facing after more than two years of remote learning during the global pandemic, and how education systems can mitigate these learning losses.

Publication | 13 May 2022

Potential Economic Impact of COVID-19-Related School Closures

This study examines the economic impacts of COVID-19-related school closures in the primary, secondary, and tertiary levels along with the implications to future labor productivity in Asia and the Pacific.

Publication | 08 Apr 2022

Compound Risk Analysis of Natural Hazards and Infectious Disease Outbreaks

This study explores the potential impacts of compounding risk between natural hazards and infectious disease outbreaks such as the recent COVID-19 pandemic in the Central Asia Regional Economic Cooperation (CAREC) region.

Article | 13 Sep 2021

ADB’s COVID-19 Response for Developing Asia Surpasses $20 Billion

ADB’s committed assistance to help its developing member countries address the COVID-19 pandemic including vaccination support has surpassed $20 billion

ADB’s COVID-19 response consists of a $20 billion package announced in April 2020 and the $9 billion Asia Pacific Vaccine Access Facility (APVAX) announced in December 2020.

ADB’s initial $20 billion COVID-19 response package supports its developing member countries in countering the severe macroeconomic and health impacts caused by COVID-19, including $2.5 billion in concessional and grant resources, as well as $2 billion earmarked for the private sector (non-sovereign).

ADB's $9 billion APVAX vaccine initiative offers rapid and equitable support to its developing member countries as they procure and deliver effective and safe COVID-19 vaccines.

Committed Amount is the financing approved by ADB's Board of Directors or Management for which the legal agreement has been signed by the borrower, recipient, or the investee company and ADB.
*Projects may be listed in more than one country or subregion. The number of projects excludes short-term finance transactions under the Trade Finance, Supply Chain Finance, and Microfinance Programs.

News and Multimedia   Subscribe to our newsletter

Publications and Documents


Made with Flourish